CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 502 enrolled
Drug / intervention
Active +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03691831
NCT03691831Phase 3Completed

A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts

Aclaris Therapeutics, Inc.·interventional·Posted Oct 2, 2018·Updated Oct 27, 2020

In Brief

A Phase 3 clinical trial evaluating Active and Vehicle for Common Wart. Completed, enrolled 502 participants across 24 sites.

Detailed Summary

Phase 3 Study of A-101 Topical Solution in Subjects with Common Warts

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Wart
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedOct 2, 2018
Enrollment StartSep 13, 2018
Primary CompletionApr 21, 2019
Study CompletionJul 9, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.8 years ago

Interventions

Activedrug

A-101 45% (hydrogen peroxide 45% topical solution)

Vehicleother

Vehicle solution containing isopropyl alcohol and water